2.70
10.89%
-0.33
시간 외 거래:
2.75
0.05
+1.85%
Cabaletta Bio Inc 주식(CABA)의 최신 뉴스
Cabaletta Bio Reports Q3 2024 Financial Results - TipRanks
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 - The Manila Times
Cabaletta Bio’s (CABA) Buy Rating Reiterated at HC Wainwright - Defense World
Cabaletta Bio Reports Q3 2024 Financial Results and Clinical Trial Advancements - MyChesCo
Cabaletta Bio (NASDAQ:CABA) Given New $12.00 Price Target at Wells Fargo & Company - MarketBeat
Cabaletta Bio stock hits 52-week low at $3.47 amid market challenges - Investing.com UK
Cabaletta Bio (NASDAQ:CABA) Earns "Buy" Rating from HC Wainwright - MarketBeat
T. Rowe Price Investment Management, Inc. Reduces Stake in Cabal - GuruFocus.com
Guggenheim maintains Buy on Cabaletta Bio with $23 target - Investing.com
Guggenheim maintains Buy on Cabaletta Bio with $23 target By Investing.com - Investing.com UK
Cabaletta Bio Inc. (CABA) Quarterly 10-Q Report - Quartzy
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Cabaletta Bio to Spotlight Groundbreaking Cell Therapies at Guggenheim’s Healthcare Innovation Conference! - MSN
Cabaletta Bio to Spotlight Groundbreaking Cell Therapies at Guggenheim's Healthcare Innovation Conference! - MyChesCo
Cabaletta Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference - The Manila Times
Vanguard Group Inc's Strategic Acquisition of Cabaletta Bio Inc Shares - GuruFocus.com
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
UBS Initiates Coverage of Cabaletta Bio (CABA) with Buy Recommendation - MSN
We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate - Yahoo Finance
Cabaletta Bio, Inc. (NASDAQ:CABA) Short Interest Down 28.9% in October - MarketBeat
Undercovered Dozen: CorMedix, Cabaletta, Skyx Platforms, Dynex Capital + - Seeking Alpha
Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash - Seeking Alpha
State Street Corp's Strategic Reduction in Cabaletta Bio Inc Holdings - Yahoo Finance
State Street Corp's Strategic Reduction in Cabaletta Bio Inc Hol - GuruFocus.com
Short Interest in Cabaletta Bio, Inc. (NASDAQ:CABA) Drops By 16.7% - MarketBeat
Trading Day Review: Cabaletta Bio Inc (CABA) Gains Momentum, Closing at 4.21 - The Dwinnex
Millennium Management LLC Grows Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential - MSN
UBS sees significant upside for Cabaletta Bio despite recent share decline - Investing.com India
Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential (NASDAQ:KYTX) - Seeking Alpha
Healthy Upside Potential: Cabaletta Bio Inc (CABA) - SETE News
UBS sees significant upside for Cabaletta Bio despite recent share decline By Investing.com - Investing.com South Africa
Cabaletta Bio (NASDAQ:CABA) Now Covered by Analysts at UBS Group - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
A Guide To The Risks Of Investing In Cabaletta Bio Inc (CABA) - Knox Daily
Cabaletta Bio Inc (CABA) stock analysis: A comprehensive overview - US Post News
Cabaletta Bio Outlines Future Trials and Development Strategy - TipRanks
Squarepoint Ops LLC Has $2.36 Million Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Marshall Wace LLP Grows Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Get in on Cabaletta Bio Inc’s (CABA) buy-in window today! - SETE News
Should investors be concerned about Cabaletta Bio Inc (CABA)? - US Post News
Cabaletta Bio Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle
Cabaletta Bio secures lease terms through August 2026 - Investing.com India
Cabaletta Bio secures lease terms through August 2026 By Investing.com - Investing.com South Africa
Ratios Reveal: Breaking Down Cabaletta Bio Inc (CABA)’s Financial Health - The Dwinnex
Perceptive Advisors LLC Cuts Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Lynx1 Capital Management LP Lowers Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Wall Street SWOT: Cabaletta Bio stock pioneers CAR-T in immunology amid challenges - Investing.com
Lynx1 Capital Management LP Has $3.68 Million Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Cabaletta Bio to Present Key Findings on CABA-201 at ACR Convergence 2024 - MSN
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024 - ForexTV.com
Deerfield Management Company L.P. Series C Reduces Stock Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR - EIN News
Cabaletta Bio Inc (CABA) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Cabaletta Bio Inc Inc. (CABA) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
Balance Sheet Breakdown: Cabaletta Bio Inc (CABA)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Technical analysis of Cabaletta Bio Inc (CABA) stock chart patterns - US Post News
Nothing is Better Than Cabaletta Bio Inc (CABA) stock at the moment - SETE News
Cabaletta Bio Inc: Navigating Market Fluctuations with a 204.68M Market Cap - The InvestChronicle
자본화:
|
볼륨(24시간):